S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:CNXC

Concentrix (CNXC) Stock Price, News & Analysis

$55.19
+0.44 (+0.80%)
(As of 04/19/2024 ET)
Today's Range
$54.23
$55.52
50-Day Range
$54.75
$84.49
52-Week Range
$54.22
$110.49
Volume
469,547 shs
Average Volume
691,774 shs
Market Capitalization
$3.64 billion
P/E Ratio
11.38
Dividend Yield
2.19%
Price Target
$82.25

Concentrix MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
49.0% Upside
$82.25 Price Target
Short Interest
Healthy
4.58% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-1.16
Upright™ Environmental Score
News Sentiment
0.84mentions of Concentrix in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$67,269 Bought Last Quarter
Proj. Earnings Growth
11.60%
From $11.03 to $12.31 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

5.00 out of 5 stars

Business Services Sector

1st out of 299 stocks

Business Services, Not Elsewhere Classified Industry

1st out of 89 stocks

CNXC stock logo

About Concentrix Stock (NASDAQ:CNXC)

Concentrix Corporation engages in the provision of technology-infused customer experience (CX) solutions worldwide. The company provides CX process optimization, technology innovation, front- and back-office automation, analytics, and business transformation services, across various channels of communication, such as voice, chat, email, social media, asynchronous messaging, and custom applications. It also offers customer lifecycle management; customer experience/user experience strategy and design; analytics and actionable insights; digital transformation services that design and engineer CX solutions to enable efficient customer self-service and build customer loyalty; customer engagement solutions and services that address the entirety of the customer lifecycle; AI technology that can intelligently act on customer intent to improve customer experience with non-human engagement; voice of the customer and analytics solutions to gather and analyze customer feedback to foster loyalty to, and growth with, clients; analytics and consulting solutions that synthesize data and provide professional insight to improve clients' customer experience strategies; vertical business process outsourcing (BPO) services; and back office BPO services that support clients in non-customer facing areas. The company's clients include technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, healthcare, and others, as well as global IPOs, social brands, and banks. Concentrix Corporation was founded in 2004 and is based in Newark, California.

CNXC Stock Price History

CNXC Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
10 Buy-Rated Stocks with Latest Insider Purchases
How Is The Market Feeling About Concentrix?
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Concentrix Reports First Quarter 2024 Results
CNXC Apr 2024 50.000 call
CNXC Oct 2024 75.000 put
CNXC Oct 2024 55.000 call
CNXC Jul 2024 35.000 put
CNXC Apr 2024 90.000 put
CNXC Apr 2024 80.000 put
See More Headlines
Receive CNXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concentrix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/15 Dividend
2/02/2024
Dividend Payable
2/15/2024
Last Earnings
3/26/2024
Today
4/20/2024
Ex-Dividend for 5/7 Dividend
4/25/2024
Dividend Payable
5/07/2024
Next Earnings (Estimated)
6/26/2024
Fiscal Year End
11/30/2024

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:CNXC
Fax
N/A
Employees
440,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$82.25
High Stock Price Target
$115.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+49.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$313.84 million
Pretax Margin
4.60%

Debt

Sales & Book Value

Annual Sales
$7.11 billion
Cash Flow
$14.80 per share
Book Value
$62.15 per share

Miscellaneous

Free Float
64,012,000
Market Cap
$3.64 billion
Optionable
Optionable
Beta
0.48
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

CNXC Stock Analysis - Frequently Asked Questions

Should I buy or sell Concentrix stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concentrix in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CNXC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNXC, but not buy additional shares or sell existing shares.
View CNXC analyst ratings
or view top-rated stocks.

What is Concentrix's stock price target for 2024?

4 Wall Street analysts have issued 1 year target prices for Concentrix's shares. Their CNXC share price targets range from $60.00 to $115.00. On average, they anticipate the company's share price to reach $82.25 in the next twelve months. This suggests a possible upside of 49.0% from the stock's current price.
View analysts price targets for CNXC
or view top-rated stocks among Wall Street analysts.

How have CNXC shares performed in 2024?

Concentrix's stock was trading at $98.21 at the start of the year. Since then, CNXC stock has decreased by 43.8% and is now trading at $55.19.
View the best growth stocks for 2024 here
.

When is Concentrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 26th 2024.
View our CNXC earnings forecast
.

How were Concentrix's earnings last quarter?

Concentrix Co. (NASDAQ:CNXC) released its quarterly earnings data on Tuesday, March, 26th. The company reported $2.33 earnings per share for the quarter, missing the consensus estimate of $2.36 by $0.03. The firm earned $2.40 billion during the quarter, compared to analyst estimates of $2.38 billion. Concentrix had a trailing twelve-month return on equity of 17.70% and a net margin of 3.53%.

How often does Concentrix pay dividends? What is the dividend yield for Concentrix?

Concentrix declared a quarterly dividend on Tuesday, March 26th. Shareholders of record on Friday, April 26th will be paid a dividend of $0.303 per share on Tuesday, May 7th. This represents a $1.21 dividend on an annualized basis and a yield of 2.20%. The ex-dividend date of this dividend is Thursday, April 25th. This is an increase from the stock's previous quarterly dividend of $0.30.
Read our dividend analysis for CNXC
.

Is Concentrix a good dividend stock?

Concentrix (NASDAQ:CNXC) pays an annual dividend of $1.21 per share and currently has a dividend yield of 2.21%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 24.95%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CNXC will have a dividend payout ratio of 9.83% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CNXC.

What ETFs hold Concentrix's stock?
What guidance has Concentrix issued on next quarter's earnings?

Concentrix updated its FY 2024 earnings guidance on Tuesday, March, 26th. The company provided EPS guidance of 11.690-12.500 for the period, compared to the consensus EPS estimate of 11.960. The company issued revenue guidance of $9.5 billion-$9.7 billion, compared to the consensus revenue estimate of $9.6 billion.

When did Concentrix IPO?

Concentrix (CNXC) raised $75 million in an initial public offering on Wednesday, July 1st 2015. The company issued 5,000,000 shares at a price of $15.00 per share. BofA Merrill Lynch, Wells Fargo Securities, Citigroup, Jefferies, Scotia Howard Weil, Credit Suisse, J.P. Morgan, Evercore ISI, BB&T Capital Markets, Goldman, Sachs, The Huntington Investment Company, Stifel and Nomura acted as the underwriters for the IPO and Clarksons Platou Securities, Cowen and Company and Tuohy Brothers were co-managers.

Who are Concentrix's major shareholders?

Concentrix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.44%), Alaska Permanent Fund Corp (0.05%), State of Michigan Retirement System (0.02%), Wealth Enhancement Advisory Services LLC (0.02%), Thompson Investment Management Inc. (0.01%) and First Hawaiian Bank (0.01%). Insiders that own company stock include Andre S Valentine, Ann F Vezina, Cormac J Twomey, Dennis Polk, Jane Fogarty, Kathryn Hayley, Matthew J Cox, Matthew Miau, Richard Rosso and Star Developments Ltd Silver.
View institutional ownership trends
.

How do I buy shares of Concentrix?

Shares of CNXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNXC) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners